301060 Stock Overview
Shanghai Labway Clinical Laboratory Co., Ltd.
Shanghai Labway Clinical Laboratory Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥21.12|
|52 Week High||CN¥61.20|
|52 Week Low||CN¥17.91|
|1 Month Change||-27.55%|
|3 Month Change||-42.53%|
|1 Year Change||12.52%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||15.60%|
Recent News & Updates
|301060||CN Healthcare||CN Market|
Return vs Industry: 301060 exceeded the CN Healthcare industry which returned -23.7% over the past year.
Return vs Market: 301060 exceeded the CN Market which returned -19.2% over the past year.
|301060 Average Weekly Movement||6.7%|
|Healthcare Industry Average Movement||5.1%|
|Market Average Movement||5.8%|
|10% most volatile stocks in CN Market||9.3%|
|10% least volatile stocks in CN Market||3.8%|
Stable Share Price: 301060 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 301060's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
Shanghai Labway Clinical Laboratory Co., Ltd. offers sales services for in vitro diagnostic products; and medical laboratory services. Shanghai Labway Clinical Laboratory Co., Ltd.
Shanghai Labway Clinical Laboratory Fundamentals Summary
|301060 fundamental statistics|
Is 301060 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|301060 income statement (TTM)|
|Cost of Revenue||CN¥1.73b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.34|
|Net Profit Margin||17.48%|
How did 301060 perform over the long term?See historical performance and comparison
1.4%Current Dividend Yield
Is 301060 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 301060?
Other financial metrics that can be useful for relative valuation.
|What is 301060's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 301060's PE Ratio compare to its peers?
|301060 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
000950 C.Q. Pharmaceutical Holding
600211 Tibet Rhodiola Pharmaceutical Holding
000078 Shenzhen Neptunus Bioengineering
600713 NanJing Pharmaceutical
301060 Shanghai Labway Clinical Laboratory
Price-To-Earnings vs Peers: 301060 is good value based on its Price-To-Earnings Ratio (15.8x) compared to the peer average (49.8x).
Price to Earnings Ratio vs Industry
How does 301060's PE Ratio compare vs other companies in the CN Healthcare Industry?
Price-To-Earnings vs Industry: 301060 is good value based on its Price-To-Earnings Ratio (15.8x) compared to the CN Healthcare industry average (21x)
Price to Earnings Ratio vs Fair Ratio
What is 301060's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||15.8x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 301060's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 301060 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 301060 (CN¥21.12) is trading above our estimate of fair value (CN¥7.57)
Significantly Below Fair Value: 301060 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Shanghai Labway Clinical Laboratory forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Labway Clinical Laboratory has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Check out Shanghai Labway Clinical Laboratory's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
How has Shanghai Labway Clinical Laboratory performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 301060 has a high level of non-cash earnings.
Growing Profit Margin: 301060's current net profit margins (17.5%) are higher than last year (10.7%).
Past Earnings Growth Analysis
Earnings Trend: 301060's earnings have grown significantly by 36.9% per year over the past 5 years.
Accelerating Growth: 301060's earnings growth over the past year (231.6%) exceeds its 5-year average (36.9% per year).
Earnings vs Industry: 301060 earnings growth over the past year (231.6%) exceeded the Healthcare industry -2.5%.
Return on Equity
High ROE: 301060's Return on Equity (32.6%) is considered high.
Discover strong past performing companies
How is Shanghai Labway Clinical Laboratory's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 301060's short term assets (CN¥2.7B) exceed its short term liabilities (CN¥1.0B).
Long Term Liabilities: 301060's short term assets (CN¥2.7B) exceed its long term liabilities (CN¥54.7M).
Debt to Equity History and Analysis
Debt Level: 301060 has more cash than its total debt.
Reducing Debt: 301060's debt to equity ratio has reduced from 7.3% to 5.5% over the past 5 years.
Debt Coverage: 301060's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 301060 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Shanghai Labway Clinical Laboratory current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Shanghai Labway Clinical Laboratory Dividend Yield vs Market|
|Company (Shanghai Labway Clinical Laboratory)||1.4%|
|Market Bottom 25% (CN)||0.5%|
|Market Top 25% (CN)||2.2%|
|Industry Average (Healthcare)||1.2%|
|Analyst forecast in 3 Years (Shanghai Labway Clinical Laboratory)||n/a|
Notable Dividend: 301060's dividend (1.42%) is higher than the bottom 25% of dividend payers in the CN market (0.55%).
High Dividend: 301060's dividend (1.42%) is low compared to the top 25% of dividend payers in the CN market (2.16%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether 301060's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if 301060's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (21.1%), 301060's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: 301060 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Weixiong Zeng (54 yo)
Mr. Weixiong Zeng serves as Chairman of the Board and General Manager at Shanghai Labway Clinical Laboratory Co., Ltd.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Shanghai Labway Clinical Laboratory Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Shanghai Labway Clinical Laboratory Co., Ltd.
- Ticker: 301060
- Exchange: SZSE
- Founded: 1993
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: CN¥8.459b
- Shares outstanding: 400.52m
- Website: https://www.labway.cn
Number of Employees
- Shanghai Labway Clinical Laboratory Co., Ltd.
- Building 1, Lane 268
- 5th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|301060||SZSE (Shenzhen Stock Exchange)||Yes||Domestic Shares||CN||CNY||Sep 2021|
|301060||XSEC (Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect)||Yes||Domestic Shares||CN||CNY||Sep 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/07 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.